How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
AI startup Anthropic's claim of automating COBOL modernization sent IBM's stock plummeting, wiping billions off its market value. The decades-old language, still powering critical systems, faces a ...
The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results